Jerald P. Radich, MD, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, elaborates on the exploratory biomarker analysis results from the ENESTnd trial (NCT00471497). In this study, it was determined that gene expression signatures can distinguish deep molecular responses from poor response in chronic myeloid leukemia (CML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).”